Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacotherapy to Improve Motor Gains of Robot-Assisted Rehabilitation in Stroke Survivors
NCT07588932Phase 1Recruiting
- Sponsor
- Spaulding Rehabilitation Hospital
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of telmisartan, cilostazol and liquid metformin (Aspargo Labs) in ischemic stroke, sponsored by Spaulding Rehabilitation Hospital. Primary endpoint: Fugl-Meyer Assessment - Upper Extremity at 12 weeks. Started May 2026; status: recruiting.
02
Drugs
telmisartancilostazolliquid metformin (Aspargo Labs)
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07588932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07588932.